Demcizumab Biosimilar - Research Grade

Human

DLL4

>1mg/ml

IgG2 - kappa

CHO Cells

Anti-Mouse DLL4 (HMD4-2) In Vivo Antibody - Low Endotoxin (ICH1269), Enoticumab Biosimilar - Research Grade (ICH5526)

https://www.imgt.org/mAb-DB/

ICH3002

Q9NR61

Blue ice

This product is a research-grade biosimilar of demcizumab, supplied as an unconjugated, non-therapeutic analogue of the originator antibody for research use only. It is not a clinical drug and is not intended for diagnostic or therapeutic applications. The molecule reproduces the binding specificity of demcizumab, a humanized IgG2 kappa antibody directed against human Delta-like ligand 4 (DLL4, UniProt Q9NR61), a Notch pathway ligand implicated in tumor angiogenesis and cancer stem cell maintenance. Because it is built around the DLL4 target rather than around a defined hybridoma clone, this reagent is intended to support functional and in-vitro investigation of DLL4-Notch biology, ligand-blocking mechanisms, and comparability or bridging studies against the reference molecule. It is manufactured to research-grade specifications with low endotoxin content (typically <1 EU/mg) and is available in bulk milligram to gram quantities suitable for in-vitro assays, binding and neutralization characterization, and use as an experimental control or benchmark reagent. As with all biosimilar reagents offered here, characteristics should be confirmed by the investigator against the requirements of the specific experimental system before use. DLL4 (Delta-like ligand 4) is a membrane-bound ligand of the Notch signaling pathway, encoded by DLL4 and expressed prominently on vascular endothelium, particularly in the sprouting and tip cells of angiogenic vessels. Engagement of Notch receptors (chiefly Notch1) by DLL4 regulates endothelial tip-versus-stalk cell specification and thereby controls productive versus non-productive angiogenesis. In tumors, DLL4-Notch signaling contributes to functional vasculature and to the maintenance of chemotherapy-resistant cancer stem cell populations. Blockade of DLL4 paradoxically increases vessel sprouting while producing poorly perfused, non-functional vasculature, and can reduce cancer stem cell frequency and tumor-propagating capacity. These properties made DLL4 an attractive oncology target and underpin the mechanism of the originator antibody, which acts as a functional antagonist disrupting DLL4-Notch interaction.

Drosophila Delta homolog 4, Delta4, Delta-like protein 4

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Demcizumab biosimilar available in gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities to support bulk and high-throughput preclinical experiments.

Q: Is this research-grade Demcizumab biosimilar suitable for in vivo studies?

A: Yes, it is supplied in a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Demcizumab biosimilar target?

A: It is an unconjugated, non-therapeutic research analog of Demcizumab that binds DLL4; for research use only.